血吸虫重组BCG—Sj26GST疫苗对小鼠血清NO浓度的影响

目的研究血吸虫重组 BCG- Sj2 6 GST疫苗对小鼠血清 NO浓度的影响。方法第 1次实验用 10 6 和 10 8CFU疫苗分别皮下注射免疫 BAL B/C鼠 ,免疫后 8周用日本血吸虫尾蚴攻击 ,感染后 6周剖杀小鼠 ,同时设有 PBS对照组 ;第 2次实验用 10 6 CFU疫苗皮下和静脉分别注射免疫鼠 ,于免疫后 0、4、8、10、14和 16周各剖杀 4只 ,分离血清 ,用 NO试剂盒检测小鼠血清 NO浓度。结果发现疫苗免疫 ,尾蚴攻击后血清 NO浓度降低 ;疫苗皮下和静脉注射免疫后 4～ 16周血清 NO浓度升高 ,分别于免疫后 10周或 16周达最高水平。结论血吸虫重组 BCG- Sj2 6 GST疫苗能降低感染鼠血清 NO浓度 ,提高宿主抗血吸虫感染的保护力。     

重组BCG-Sj26GST疫苗诱导小鼠体液免疫应答的动态观察

目的　检测日本血吸虫重组BCG Sj2 6GST疫苗免疫小鼠不同时间后的血清IgG及其亚类和循环抗原 (circulat ingantigen ,CAg)反应。方法　 1× 10 6克隆形成单位 (colony formingunit,CFU)疫苗皮下和静脉注射免疫BALB/c鼠 ,分别于免疫后 0、4、8、10、14和 16周各剖杀 4只 ,收集血清 ,常规ELISA法检测IgG及其亚类和CAg ,同时设PBS皮下注射对照组。结果皮下注射组IgG在免疫后 10周 ,IgG1在免疫后 14～ 16周 ,IgG2a在免疫后 4周和IgG2b在免疫后 16周达最高水平 ,未能测到CAg ;静脉注射组IgG在免疫后 10周 ,IgG1和IgG2a在免疫后 8周以及IgG2b在免疫后 16周达最高水平 ,CAg在免疫后 14周升高。结论　日本血吸虫重组BCG Sj2 6GST疫苗能诱导宿主产生高水平的IgG、IgG2a和IgG2b ,静脉注射的免疫效果优于皮下注射     

日本血吸虫感染小鼠肠系膜淋巴结T细胞亚群的变化

目的:观察C57BL/6小鼠感染日本血吸虫(Schistosome japonicum,Sj)4～6周肠系膜淋巴结T细胞亚群的改变。方法:用Sj尾蚴腹贴法建立Sj感染的小鼠模型。4～6周后取肠系膜淋巴结做淋巴细胞计数,使用细胞内细胞因子染色的方法,利用流式细胞仪检测肠系膜淋巴结淋巴细胞中分泌不同细胞因子的T细胞亚群含量的变化。结果:Sj感染C57BL/6小鼠4～6周后,肠系膜淋巴结细胞数量明显增多;流式细胞仪检测发现肠系膜淋巴结中CD4+T细胞中分泌IFN-γ的Th1细胞增多1倍,分泌IL-4和IL-5的Th2细胞增多近20倍,Th1/Th2轴发生偏移;分泌IL-17的Th17细胞也增多近5倍;分泌IFN-γ的CD8+T细胞也增多1倍。结论:日本血吸虫感染C57BL/6小鼠4～6周肠系膜淋巴结细胞增多,并向Th2和Th17型细胞极化。     

铜绿假单胞菌重组Bb-OprF疫苗诱导小鼠细胞免疫应答的研究

目的研究铜绿假单胞菌重组双歧杆菌(rBb)-OprF疫苗免疫小鼠,PAO1株攻击后产生的细胞免疫应答。方法将rBb-OprF疫苗分别采用皮下注射、肌肉注射、鼻腔黏膜和口服灌胃4种途径免疫Balb/c小鼠,免疫后8周用5×106CFU的PAO1株攻击,攻击1周后杀鼠取脾,MTT法检测特异性脾淋巴细胞增殖,流式细胞术检测脾CD4+T和CD8+T细胞比率,用ELISA法检测脾细胞培养上清IFN-γ、IL-12、TNF-α和IL-10的水平。结果脾T淋巴细胞增殖明显;脾细胞CD4+和CD8+T细胞亚群显著增加;脾细胞培养上清IFN-γ、IL-12、TNF-α和IL-10的水平显著升高,其中IFN-γ最为显著。结论铜绿假单胞菌rBb-OprF疫苗可诱导小鼠产生混合型的Th1和Th2免疫应答。     

细粒棘球绦虫重组BCG-Eg95疫苗免疫小鼠后脾细胞因子的动态观察

目的 动态观察细粒棘球绦虫重组BCG-Eg95疫苗免疫小鼠后脾细胞因子的变化.方法 疫苗分别采用口服灌胃和鼻腔内接种免疫Balb/e鼠,在免疫后0、2、4、6、8、10、12、14、16和周各剖杀4只小鼠取脾,分离脾细胞,用EgAg或ConA刺激培养,收集脾细胞培养上清液,用试剂盒检测脾细胞培养上清液的IL-2、IFN-у、TNF-α和IL-4水平,同时设有PBS对照.结果 口服免疫组的IL-2、IFN-у、TNF-α和IL-4水平分别在免疫后4～10周、2～10周,2～18周和10周升高,分别在免疫后10、10、6和10周达最高水平;鼻腔内接种组的IL-2、IFN-у、TNF-α和IL-4水平分别在免疫后2～18周、2～10周、2～18周和10周升高,分别在免疫后10、8、12和10周达最高水平.结论 细粒棘球绦虫重组BCG-Eg95疫苗在免疫早期(2～10周)可诱导小鼠脾细胞产生Th1和Th2.混合型细胞因子.     

日本血吸虫重组Bb(pGEX-Sj14-3-3)疫苗免疫小鼠脾细胞因子的动态观察

目的探讨日本血吸虫重组双歧杆菌属两歧双歧杆菌(Bifidobacterium bifidum,Bb)(pGEX-Sj14-3-3)疫苗免疫Balb/c小鼠后脾细胞因子的动态变化。方法重组疫苗分别经口服灌胃及鼻腔粘膜接种小鼠;在免疫后0、2、4、6、8、10、12、14、16、18、20和22周各剖杀4只小鼠,取脾及分离脾细胞;脾细胞分别经未刺激、SjAWA和ConA刺激培养;收集培养的上清液,双抗体夹心ELISA法测定培养上清液的细胞因子水平。结果口服组小鼠脾细胞IFN-γ、IL-12、TNF-α和IL-10水平分别在免疫后2~12、6~8、2~12和2~8周显著升高,分别在免疫后8、8、6和4周达最高水平;鼻腔黏膜接种组小鼠脾细胞IFN-γ、IL-12、TNF-α和IL-10水平分别在免疫后2~20、2~10、2~16和2~16周显著升高,分别在免疫后2、2、4和4周达最高水平。结论重组Bb(pGEX-Sj14-3-3)疫苗能够诱导免疫小鼠产生有效的免疫应答。     

血吸虫重组卡介苗--Sj26GST疫苗的有关毒性研究

由于BCG免疫效果不够理想 ,以及结核分枝杆菌耐药性的产生 ,促使人们开始研制新的结核病疫苗。利用BCG独特的安全性和免疫佐剂作用和日本血吸虫中相对分子量为 2 6× 10 3 的谷光甘肽S转移酶 (Sj2 6GST)的良好免疫原性 ,已经构建出了一种重组卡介苗———Sj2 6GST(rBG Sj2 6GST)。我们就这种疫苗对小鼠的毒性进行了研究 ,从而为疫苗的安全性提供实验依据。将rBG Sj2 6GST疫苗及BCG、含质作者单位 :华中科技大学同济医学院病原生物学系 (蔡昌学 ,叶嗣颖 ,常燕子 ) ;湖北药检专科学校检验系微生物学及免疫学教研室 (胡佳杰 )通讯…     

日本血吸虫重组Bb(pGEX-Sj14-3-3)疫苗免疫BALB/c小鼠诱导免疫应答的动态检测

目的 研究日本血吸虫重组双歧杆菌属两歧双歧杆菌(Bb) (pGEX-Sjl4-3-3)疫苗免疫小鼠后其免疫应答的动态变化.方法 将重组疫苗分别采用口服灌胃和鼻内接种免疫BALB/c小鼠,分别于免疫后2、4、6、8、10、12、14、16、18、20和22周ELISA法测小鼠血清中IgG及其亚类、IgE和IgA及脾细胞培养液中IFN-γ、IL-12、TNF-α和IL-10水平;MTT法测定脾细胞增殖;流式细胞仪检测脾细胞凋亡率及CD4+和CD8+T细胞亚群百分率.结果 口服组血清IgG、IgG1、IgG2a、IgG2b、IgG3、IgE和IgA水平分别在免疫后8、6、6、4、8、10和6周达峰值.脾淋巴细胞增殖和凋亡水平均在免疫后4周达峰值;CD4+T细胞于8周达峰值,CD8+T细胞于14周达峰值.IFN-γ、IL-12、TNF-α和IL-10水平分别于8、8、6和4周达峰值.鼻内接种组血清IgG、IgG1、IgG2a、IgG2b、IgG3、IgE和IgA分别于4、6、4、4、8、10和8周达峰值.脾淋巴细胞增殖及凋亡水平也均在4周达峰值;CD4+T细胞于8周达峰值,CD8+T细胞于4周达峰值.IFN-γ、IL-12、TNF-α和IL-10水平分别于2、2、4和4周达峰值.口服及鼻腔内接种是两种较好的免疫途径,且后者优于前者.结论 该疫苗可诱导小鼠产生有效的免疫应答.     

多房棘球绦虫重组BCG-EmⅡ/3疫苗促进小鼠脾细胞因子的分泌

目的动态观察多房棘球绦虫重组BCG-EmⅡ/3疫苗免疫小鼠后脾细胞因子的变化。方法采用鼻腔内接种疫苗免疫BALB/C鼠,在免疫后0、2、4、6、8和10周各剖杀4只小鼠取脾,分离脾细胞,用EmAg或ConA刺激培养,收集脾细胞培养上清液,检测脾细胞培养上清液中的IL-2、IFN-γ、TNF-α和IL-4水平,同时设有PBS对照。结果疫苗接种组中IL-2、IFN-γ、TNF-α和IL-4分别在免疫后2~6、2~6、2~10和8~10周升高,分别在免疫后4、4、8和10周达最高水平。结论多房棘球绦虫重组BCG-EmⅡ/3疫苗在免疫早期(2~8周)即可诱导小鼠产生一个TH1型保护性免疫反应。     

CpG协同calpain DNA疫苗诱导BALB/c鼠TH1免疫应答和抗日本血吸虫感染

目的 探讨含非甲基化CpG单核苷酸(cpG-ODN)协同calpain DNA疫苗抗日本血吸虫感染的保护性作用、诱导的免疫应答类型及其免疫机理。方法 calpain基因从原核表达载体pGEX-2TK亚克隆到含小鼠IL-2基因启动序列的真核表达载体pVAC，构建含日本血吸虫疫苗候选分子calpain基因的真核表达体系pVAC-calpain的DNA疫苗，构建的DNA疫苗与CpGODN免疫BALB/c小鼠，在不同阶段采血测定免疫鼠抗体的动态变化、RT-PCR分析免疫鼠细胞因子IFN-γ、IL-4、IL-12的表达，加强免疫1周后用日本血吸虫尾蚴攻击感染免疫鼠，用减虫率、减卵率及其病理组织学指标考核保护性免疫的效果。结果 pVAC-calpain的DNA疫苗体系诱导了IgG抗体的产生，免疫3周后细胞因子IFN-γ、IL-4、IL-12的表达表现出差异。特别是在CpG-ODN和pVAG-calpain免疫组IFN-γ、IL-12有高度表达，而IL-4的表达受到相对抑制，对攻击感染的日本血吸虫表现出了45％的减虫效果，虫卵肉芽肿的面积显著性的减少。结论 Cp GODN协同日本血吸虫calpain DNA疫苗诱导了THl为主的免疫应答，并能部分抵抗日本血吸虫感染和减轻感染鼠由于TH2免疫应答所导致的虫卵肉芽肿反应，提示CpG ODN能够协同calpain DNA疫苗抗日本血吸虫感染和缓解日本血吸虫免疫病理反应。     

pHSP65疫苗增强结核杆菌特异性T细胞产生IFN-γ

为提高BCG的免疫效果,以BCG进行初次免疫,比较pHSP65基因疫苗和BCG疫苗加强免疫的效果,寻找新型结核疫苗的初免-加强免疫策略。于第0周皮下接种BCG,第6、8周给予pHSP65滴鼻免疫或BCG加强免疫,末次免疫后2周检测全身及肺脏局部IFN-γ的产生。与BCG初免/BCG加强免疫相比,经pHSP65基因疫苗滴鼻加强免疫后,ELISPOT结果显示脾脏和肺局部分泌IFN-γ的淋巴细胞数量显著增加,流式检测显示IFN-γ+CD4+T细胞数量显著增加,ELISA结果证实淋巴细胞IFN-γ的分泌显著增高,提示经BCG初次免疫后,以pHSP65 DNA滴鼻加强免疫可显著增强全身和肺局部T淋巴细胞IFN-γ的产生,具有良好的抗结核感染潜能。     

免疫复合物型增效乙型肝炎疫苗细胞免疫检测方法的建立

目的 建立免疫复合型增效乙型肝炎疫苗细胞免疫检测方法并与常规乙型肝炎疫苗进行比较。方法增效乙型肝炎疫苗肌内免疫BALB/c小鼠,Elispot方法检测小鼠脾脏淋巴细胞分泌IFN-γ的细胞频数（SFC）,优化实验条件：免疫剂量、检测时间和特异性刺激物及刺激浓度。同时将增效乙型肝炎疫苗与常规乙型肝炎疫苗进行比较。结果5μg免疫组IFN-γ SFC明显高于2μg免疫组,初次免疫后3周IFN-γ SFC开始下降,多肽刺激IFN-γ SFC高于蛋白刺激,多肽浓度为2μg即可充分刺激斑点形成;增效乙肝疫苗免疫组IFN-γ SFC高于常规乙型肝炎疫苗组。结论 初步建立了免疫复合型增效乙型肝炎疫苗细胞免疫检测方法并证明其重复性良好,其细胞免疫水平高于常规乙型肝炎疫苗。     

Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein

Intranasal immunization of mice with purified Brucella melitensis lipopolysaccharide (LPS) as a noncovalent complex with Neisseria meningitidis group B outer membrane protein (GBOMP) elicited a high-titer anti-LPS systemic antibody response and a significant mucosal antibody response. The anti-LPS immunoglobulin G (IgG) antibody was predominantly of the IgG1 subtype, although there was some response of the IgG2a, IgG2b, and IgG3 subtypes. The antibody titer remained high for 16 weeks postimmunization. Immunized mice and sham-immunized control mice were challenged intranasally with 10(4) CFU of virulent B. melitensis strain 16 M 4 weeks after the second dose of vaccine. The numbers of bacteria in lungs, livers, and spleens at 3 days, 9 days, and 8 weeks postchallenge were determined. Bacteria were found in lungs of all mice on day 3, but there was no disseminated infection of liver or spleen. By day 9, 40% of the mice had infected spleens and livers. At 8 weeks postchallenge, spleens of 25 of 62 immunized mice were infected, compared to 61 of 62 control mice (P < 0.0001). The livers of 12 of 43 immunized mice were infected, compared to 22 of 36 control mice (P = 0.005). In contrast, the lungs of 26 of 46 immunized mice were still infected, compared to 27 of 44 control mice. The numbers of bacterial CFU in lungs of immunized and control animals were identical. These studies show that intranasal immunization with B. melitensis LPS-GBOMP subunit vaccine significantly protects mice against intranasal challenge with virulent B. melitensis. Vaccination reduces bacterial dissemination to spleen and liver but has no effect on the course of lung infection.     

Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine

Groups of mice were immunized either subcutaneously or intranasally with purified Brucella melitensis lipopolysaccharide (LPS) or with LPS as a noncovalent complex with Neisseria meningitidis group B outer membrane protein (LPS-GBOMP). Control mice were inoculated with sterile saline. Two doses of vaccine were given 4 weeks apart. Mice were challenged intranasally with virulent B. melitensis strain 16M 4 weeks after the second dose of vaccine. Sera, spleens, lungs, and livers of mice were harvested 8 weeks after challenge. The bacterial loads in the organs were determined by culture on brucella agar plates. Protective efficacy was determined by comparing the clearance of bacteria from organs of immunized mice with the clearance of bacteria from organs of control mice. At 8 weeks postchallenge there was significant protection from disseminated infection of spleens and livers of mice intranasally immunized with either vaccine compared to infection of control mice (P < 0.01). There was no significant difference in clearance of bacteria from the lungs of immunized mice and control mice. However, mice immunized subcutaneously with either LPS or LPS-GBOMP vaccine showed significant protection against infection of the spleen (P < 0.001), liver (P < 0.001), and lungs (P < 0.05). These results show that intranasal immunization of mice with either vaccine provided significant protection against disseminated infection of the spleen and liver but subcutaneous immunization of mice with the vaccines conferred significant protection against infection of the spleen, liver, and lungs.     

Deletion of purE attenuates Brucella melitensis infection in mice.

We previously showed that a purE mutant (delta purE201) of Brucella melitensis 16M is attenuated for growth in cultured human monocytes (E. S. Drazek, H. H. Houng, R. M. Crawford, T. L. Hadfield, D. L. Hoover, and R. L. Warren, Infect. Immun. 63:3297-3301, 1995). To determine if this strain is attenuated in animals, we compared the growth of the delta purE201 mutant with that of strain 16M in BALB/c mice. The number of bacteria in the spleen and spleen weight peaked for both strains between 1 and 2 weeks postinfection (p.i.), though the number of delta purE201 cells was significantly less than the number of 16M cells recovered from the spleens of infected mice. During the next 6 weeks, delta purE201 was essentially eliminated from infected mice (three of five mice sterile; < 100 CFU in two of live mice at 8 weeks p.i.), whereas bacteria persisted at a high level in the spleens of 16M-infected mice (about 106 CFU per spleen). The number of bacteria in the livers and lungs of mice infected with either strain paralleled those in the spleen. Mice infected with 16M had a strong inflammatory response, developing dramatic and prolonged splenomegaly (five to eight times normal spleen weight) and producing serum interleukin-6. In contrast, mice infected with delta purE201 developed only mild, transient splenomegaly at 1 week p.i. and produced no interleukin-6 in their serum. We further characterized the host response to infection by measuring changes in immune spleen cell populations by flow cytometry. CD4- and CD8-positive lymphocytes declined by I week in both experimental groups, while MAC-1-positive cells increased. T-cell subpopulations remained low or declined further, and MAC-1 cells increased to three times normal levels during 8 weeks of infection with 16M but returned to normal by 4 weeks after infection with delta purE201. These results document infectivity and attenuation of delta purE201 and suggest that it should be further evaluated as a potential vaccine.     

沙眼衣原体主要外膜蛋白核酸疫苗诱导小鼠产生特异性细胞和体液免疫应答

目的构建沙眼衣原体主要外膜蛋白核酸疫苗,并观察其诱导小鼠产生的体液免疫和细胞免疫。方法将核酸疫苗(pcDNA3.1MOMP)或对照空质粒(pcDNA3.1)注射于4～6周龄小鼠后腿股四头肌,每次剂量为100mg。间隔2周加强免疫2次。末次免疫后,ELISA法测定脾淋巴细胞培养上清液中IFNγ及小鼠血清中抗MOMP水平;MTT法测定脾淋巴细胞特异性增殖反应。结果小鼠接种核酸疫苗后,能产生特异性抗体,第3次免疫后抗体最高滴度达1∶1024,培养上清液中IFNγ达(532.0±45.4)pg/mL;实验组小鼠脾淋巴细胞刺激指数为3.94±0.25,其抗原特异性反应明显高于对照组。结论沙眼衣原体主要外膜蛋白核酸疫苗能刺激机体产生特异的细胞免疫和体液免疫。     

日本血吸虫TCTP编码基因DNA免疫的效果评价

目的评价pEGFP—TCTP真核重组质粒联合免疫佐剂CpG诱导小鼠保护性免疫的效果。方法构建日本血吸虫TCTP真核重组质粒．将pEGFP—Tc口注射入BABL／c小鼠，采用ELISA法检测免疫小鼠血清中IFN-γ水平；尾蚴攻击感染后45d处死小鼠，收集成虫和虫卵，计算减虫率和减卵率；小鼠肝脏送病理切片，计算虫卵肉芽肿的数量。结果TCTP DNA免疫保护性效果显示：实验组与阴性对照组相比，显示出一定的保护性效果．TCTP组的减虫率和减卵率分别为43．91％和53．48％．与GST组效果相似。DNA免疫后及感染后期，TCTP组与PBS对照组血清IFN-γ水平有显著性差异（P〈0．05）；攻击感染前后组间比较发现，GST组和GST＋CpG组有显著性差异（P〈0．05），提示CpG显著提高了DNA免疫的效果。结论SjTCTP DNA免疫能诱导较明显的保护性Thl免疫应答。CpG基序可以有效的诱导保护性Th1免疫应答，是一种有效的DNA免疫佐剂。     

Vibriolytic IgG immunocyte response of mice after primary and secondary immunization with cholera somatic antigens.

Antibody plaque-forming cells (FC) to the somatic antigens of Vibrio cholerae were enumerated in the spleen of mice after primary and secondary immunization with a heat-killed vaccine prepared from the vibrios. Immunocytes releasing both high efficiency IgM and low efficiency IgG antibody were readily detected using a direct and facilitated plaque procedure in agar gel. Whereas the peak numbers of IgM-PFC after primary immunization occurred on days 12 to 14, the peak IgG-PFC response developed somewhat later (16-18 days). After a second injection of vaccine larger numbers of both IgM- and IgG-PFE appeared in the mouse spleens, with peak responses for both occurring between days 5 and 8. The largest number of IgG-PFC developed in spleens of mice given a second injection of vaccine 6-8 weeks after primary immunization. The dose of killed vibrios used for priming markedly affected both the magnitude and the class of antibody-forming cells appearing during the secondary response; 1--10 mug vaccine was more effective than higher or lower doses for priming the mice to a heightened secondary response. Furthermore, the antigenic specificity of both the IgM- and IgG-PFC appearing after secondary immunization was directly related to the strain of cholera bacilli used for priming. When mice were immunized with the Ogawa strains of cholera most of the secondary PFC after booster immunization with the serologically distinct Inaba strain was directed towards the common antigen shared by both strains and not to the type specific antigen of the Inaba vibrios. The specificity of the anti-vibrio PFC during both the primary and secondary responses was readily demonstrable by inhibition experiments using sonicated or soluble cholera antigens. Prior incubation of these antigens with test spleen cells in the agar gel effictively inhibited development of the vibriolytic plaques, regardless of antibody class. Similar antigen extracts from toher bacteria had no effect. The immunoglobulin nature of the plaques was also demonstrable by inhibition with low dilutions of rabbit anti-mouse globulin serum incorporated into the agar plates prior to testing; both IgM and IgG plaues were inhibited.     

Expansion of regulatory CD8+ CD25+ T cells after neonatal alloimmunization

Transplantation tolerance induced by neonatal injection of semi-allogeneic spleen cells is associated with a pathological syndrome caused by T helper type 2 (Th2) differentiation of donor-specific CD4(+) T lymphocytes. We have shown previously that this Th2-biased response is inhibited by host CD8(+) T cells. Herein, we demonstrate that upon neonatal immunization with (A/J × BALB/c)F(1) spleen cells, BALB/c mice expand a population of CD8(+) T cells expressing both CD25 and forkhead box P3 (FoxP3) markers. In this setting, CD8(+) CD25(+) T cells predominantly produce interferon (IFN)-γ and interleukin (IL)-10 and are efficient in controlling IL-4, IL-5 and IL-13 production by donor-specific CD4(+) T cells in vitro. CD8(+) FoxP3(-) T cells are single producers of IFN-γ or IL-10, whereas CD8(+) FoxP3(+) T cells are double producers of IFN-γ and IL-10. We further demonstrate that IFN-γ and IL-10 are two major cytokines produced by CD8(+) T cells involved in the in vivo regulation of Th2-type pathology. In this setting, we conclude that neonatal alloimmunization induces the expansion of several regulatory CD8(+) T cells which may control Th2 activities via IFN-γ and IL-10.     

乙型肝炎疫苗联合B7-H1蛋白疫苗对HBV转基因小鼠抗HBsAg免疫应答的影响

目的:研究B7-H1蛋白疫苗对HBV转基因小鼠免疫应答的影响,探索治疗慢性乙型肝炎的新方法。方法:用不同剂量的乙型肝炎疫苗和B7-H1蛋白疫苗联合免疫HBV转基因小鼠,应用ELISA法检测转基因小鼠在不同时间点血清抗B7-H1抗体滴度,同时在免疫后第14周末处死小鼠取脾细胞,检测不同的免疫方法对小鼠脾细胞产生HBsAg特异性Th1类细胞因子(IFN-γ及IL-2)、对HBsAg特异性分泌IFN-γT细胞数量及对小鼠淋巴细胞增殖的影响。结果:成功完成小鼠的免疫计划,5周起血清中即能测到B7-H1抗体,同一时间点各组之间的抗体滴度值并无明显差异。加B7-H1蛋白免疫各组与相同剂量单用HBsAg蛋白免疫各组相比:IL-2均明显减低(P<0.05),分泌IFN-γT的T细胞数量下降,但脾淋巴细胞分泌IFN-γ的水平各组间无明显差异;MTT法测定的淋巴细胞增殖能力各组间也无明显变化。结论:B7-H1蛋白疫苗可诱导HBV转基因小鼠产生明显的抗B7-H1抗体应答,但不能增强抗HBsAg的免疫应答。较小剂量的HBsAg即可引起HBV转基因小鼠Th1类细胞因子(IFN-γ及IL-2)的分泌以及淋巴细胞增殖。